Humanized anti-CD271 monoclonal antibody exerts an anti-tumor effect by depleting cancer stem cells.
Animals
Antibodies, Monoclonal, Humanized
/ immunology
Antibody-Dependent Cell Cytotoxicity
Apoptosis
Cell Proliferation
Female
Humans
Hypopharyngeal Neoplasms
/ drug therapy
Lung Neoplasms
/ drug therapy
Melanoma
/ drug therapy
Mice
Mice, Inbred BALB C
Mice, Inbred NOD
Mice, SCID
Neoplastic Stem Cells
/ drug effects
Nerve Tissue Proteins
/ immunology
Receptors, Nerve Growth Factor
/ immunology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Antibody therapy
Antibody-dependent cellular toxicity
CD271
Hypopharyngeal cancer
Melanoma
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
01 Oct 2019
01 Oct 2019
Historique:
received:
09
05
2019
revised:
21
06
2019
accepted:
12
07
2019
pubmed:
22
7
2019
medline:
28
5
2020
entrez:
21
7
2019
Statut:
ppublish
Résumé
CD271, known as a neurotrophin receptor, is expressed in various cancers such as hypopharyngeal cancer (HPC) and melanoma. We recently reported that CD271 is a cancer-stem-cell biomarker of HPC, and that its expression is essential for cancer-cell proliferation and is correlated with a poor prognosis in this disease. Here, to develop a therapeutic antibody to CD271, we established a humanized anti-CD271 monoclonal antibody (hCD271 mA b). hCD271 mA b bound to the cysteine-rich domain 1 (CRD1) of human CD271 with high affinity (K
Identifiants
pubmed: 31325530
pii: S0304-3835(19)30407-0
doi: 10.1016/j.canlet.2019.07.011
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
NGFR protein, human
0
Nerve Tissue Proteins
0
Receptors, Nerve Growth Factor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
144-152Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.